Abstract 5636
Background
Durvalumab, a human anti–PD-L1 mAb, is currently approved for treatment of patients with Stage III unresectable NSCLC. The objectives of this analysis were to identify prognostic and predictive factors for tumor growth and shrinkage, as well as for OS in NSCLC patients treated with durvalumab.
Methods
Longitudinal tumor size (TS) and OS data obtained from NSCLC patients in Study 1108 (all comers) and ATLANTIC (Stage III and above) who received durvalumab were analyzed using a nonlinear mixed effect model that describes the growth and regression of sensitive and insensitive tumor cells, as well as delay in immune response leading to tumor killing. A linked OS-dropout model was developed by relating model-predicted tumor changes to OS and dropout probability over time. Potential prognostic and predictive factors were evaluated in a multivariate covariate analysis using the models.
Results
The longitudinal TS and OS data from NSCLC patients in both studies are generally well described by the models. Liver metastasis, neutrophil-to-lymphocyte ratio (NLR), EGFR mutation, and durvalumab clearance (CL) are identified as prognostic factors for tumor growth, and tumor cell PD-L1 expression (TC) and baseline tumor size as predictive factors for tumor killing (p < 0.01). The significant factors for OS after accounting for the tumor size changes included TC and immune cell PD-L1 expression (IC), NLR, lactate dehydrogenase, as well as CL (p < 0.01). Among all factors tested, NLR is the most influential factor on the predicted 1-year survival rates (∼60% vs. 30% with NLR below and above the median [4.56]). Positive PD-L1 expression (TC or IC ≥ 25%) is predicted to result in ∼10-20% increase in one-year survival rates. Increasing the cutoff value is not predicted to result in substantially greater improvement in the survival rate.
Conclusions
The modeling results provided quantitative assessments of the impact of various prognostic and predictive factors, as well as biomarker cutoff values on the efficacy of durvalumab in NSCLC patients, and can be used to inform patient selection criteria in future monotherapy or combination studies.
Clinical trial identification
NCT01693562.
Legal entity responsible for the study
MedImmune, LLC.
Funding
MedImmune.
Editorial Acknowledgement
Disclosure
Y. Zheng, R. Narwal, C. Jin, P. Baverel, A. Gupta, B.W. Higgs, L. Roskos: Employee: MedImmune; Stock and/or stock interests or options: AstraZeneca. P. Mukhopadhyay: Employee, Stock and/or stock interests or options: AstraZeneca.
Resources from the same session
2060 - Relationship between ring-type dedicated breast PET and tumor-infiltrating lymphocytes in early breast cancer
Presenter: Shinsuke Sasada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2070 - Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms
Presenter: Yun Fan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2130 - Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy
Presenter: Lindsay Angus
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2446 - Quantifying circulating cell-free DNA as clinical biomarker
Presenter: MEDDEB Romain
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2958 - Gene Expression Profile (GEP) and Survival Among Patients With Advanced Ovarian Cancer
Presenter: Estrid Høgdall
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3621 - Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics.
Presenter: Dongyao Yan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3634 - Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study
Presenter: Bram De Craene
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3748 - Accurate measurement of tumor mutation burden in liquid biopsy (bTMB) using a 500 gene panel
Presenter: Tingting Jiang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3753 - Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a Phase 1/II clinical trial in mCRPC patients
Presenter: Mengyao Tan
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5062 - The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type
Presenter: Josef Dvorak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract